| Identification | Back Directory | [Name]
L-Valinamide, 3-amino-N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-buten-1-yl]-N,3-dimethyl- | [CAS]
1977557-83-7 | [Synonyms]
L-Valinamide, 3-amino-N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-4-ethoxy-3-methyl-1-(1-methylethyl)-4-oxo-2-buten-1-yl]-N,3-dimethyl- | [Molecular Formula]
C34H56N4O6 | [MOL File]
1977557-83-7.mol | [Molecular Weight]
616.83 |
| Chemical Properties | Back Directory | [Boiling point ]
738.7±60.0 °C(Predicted) | [density ]
1.074±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
13.86±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SC209 intermediate-2 (Compound A9) is an intermediate of the ADC cytotoxin SC209 (HY-144880). SC209 intermediate-2 is an ADC Linker[1]. | [References]
[1] Toni Kline, et al. Hemiasterlin derivatives for conjugation and therapy. Patent. WO2016123582. |
|
|